Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era-Reference-Cited by-同舟云学术

Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era

Published:2008-10 Issue:5 Volume:8 Page:436-442
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Montemurro Filippo,Redana Stefania,Viale Giuseppe,Sanna Giuseppina,Donadio Michela,Valabrega Giorgio,del Curto Barbara,Bottini Alberto,Botti Gerardo,Paolo dei Tos Angelo,Jacomuzzi Maria Elena,Di Bonito Maurizio,Danese Saverio,Clavarezza Matteo,Kulka Janina,Di Palma Silvana,Durando Antonio,Sapino Anna,Aglietta Massimo

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

2. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group;Marty;J Clin Oncol,2005

3. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

4. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

5. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity;Montemurro;Expert Opin Biol Ther,2007

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis

;Cancer Management and Research;2019-05

2. Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells;Breast Cancer;2016-05-06

3. Lapatinib: An Oral Dual Tyrosine Kinase Inhibitor for HER-2-Positive Breast Cancer;Women's Health;2015-05

4. Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario;Expert Opinion on Biological Therapy;2014-09-24

5. Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients;Journal of Chemotherapy;2013-12